United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field. byVenkateshJanuary 9, 2026